Growth Metrics

TriSalus Life Sciences (TLSI) Free Cash Flow (2022 - 2026)

TriSalus Life Sciences has reported Free Cash Flow over the past 5 years, most recently at -$6.6 million for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 26.04% year-over-year to -$6.6 million; the TTM value through Mar 2026 reached -$19.4 million, up 45.33%, while the annual FY2025 figure was -$18.1 million, 56.1% up from the prior year.
  • Free Cash Flow for Q1 2026 was -$6.6 million at TriSalus Life Sciences, down from -$2.5 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$425954.0 in Q1 2022 and troughed at -$22.9 million in Q3 2022.
  • A 5-year average of -$8.8 million and a median of -$8.5 million in 2022 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: plummeted 2367.4% in 2023 and later surged 65.41% in 2025.
  • Year by year, Free Cash Flow stood at -$8.5 million in 2022, then fell by 12.16% to -$9.5 million in 2023, then soared by 36.62% to -$6.1 million in 2024, then skyrocketed by 58.87% to -$2.5 million in 2025, then tumbled by 166.01% to -$6.6 million in 2026.
  • Business Quant data shows Free Cash Flow for TLSI at -$6.6 million in Q1 2026, -$2.5 million in Q4 2025, and -$3.8 million in Q3 2025.